menu
    • menu

    Company profile for Global Blood Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. We have one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Global Blood TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    171 Oyster Point Boulevard, Suite 300 South San Francisco, CA 94080
    Telephone
    Telephone
    1-833-428-2677
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gbt.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/global-blood-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/gbt_news

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer to press pause on large M&A deals, CEO says
    Pfizer to press pause on large M&A deals, CEO says

    11 Jun 2024

    // Fraiser Kansteiner FIERCE PHARMA

    https://www.fiercepharma.com/pharma/pfizer-ceo-says-company-needs-take-breathing-period-after-massive-ma-stretch

    Fraiser Kansteiner FIERCE PHARMA
    11 Jun 2024
    Share Share
    Pfizer to end licence deal with Syros for blood disorder therapies
    Pfizer to end licence deal with Syros for blood disorder therapies

    22 Jul 2023

    // BUSINESS TIMES

    https://www.businesstimes.com.sg/companies-markets/pfizer-end-licence-deal-syros-blood-disorder-therapies

    BUSINESS TIMES
    22 Jul 2023
    Share Share
    Global Blood Therapeutics' Oxbryta (voxelotor) Receives Approval in Europe
    Global Blood Therapeutics' Oxbryta (voxelotor) Receives Approval in Europe

    13 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/oxbryta-epar-medicine-overview_en.pdf

    EMA
    13 Jun 2023
    Share Share
    GBT and Sickle Cell Disease Association of America to Host 11th
    GBT and Sickle Cell Disease Association of America to Host 11th

    08 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/08/2512447/37049/en/GBT-and-Sickle-Cell-Disease-Association-of-America-to-Host-11th-Annual-Sickle-Cell-Disease-Therapeutics-Conference.html

    GLOBENEWSWIRE
    08 Sep 2022
    Share Share
    J&J lost to Pfizer in $5.4B GBT bidding war: Bloomberg
    J&J lost to Pfizer in $5.4B GBT bidding war: Bloomberg

    24 Aug 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/johnson-johnson-lost-pfizer-global-blood-therapeutics-bidding-war-bloomberg

    Angus Liu FIERCEPHARMA
    24 Aug 2022
    Share Share
    How Pfizer became interested in GBT and reached the $5.4B buy
    How Pfizer became interested in GBT and reached the $5.4B buy

    23 Aug 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/how-pfizer-became-interested-global-blood-and-beat-deal-talk-firstcomer-54b-acquisition

    Angus Liu FIERCEPHARMA
    23 Aug 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search